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Introduction: homografts have been used since the early days of vascular surgery, but have failed to provide long-term
success. Arteries supplying organ transplants seldom show signs of biodegradation. We therefore introduced fresh arterial
homograft repair with consecutive immunosupression (ATX).
Aim: to assess feasibility and clinical usefulness of ATX
Setting: university teaching hospital.
Material and Method: conduits were harvested during multi-organ procurement and stored in Custodiol1. Implantation
followed immediately. Viability of the transplant was documented in all cases. Patients received immunosuppession for the
duration of bypass function.
Results: thirteen patients received ATX for critical limb ischaemia (M/F: 11/2, age: 62 yr, previous revascularisations:
4.5 (1±8), median run-off index 5, previous organ transplant: n 2. Most bypasses were anastomosed to single tibial or
pedal vessels. There was no early failure. Within an average follow up of 12 months there were 6 graft thromboses in
5 patients, successfully revised in 4. Three limbs were lost after 2, 5 and 6 months due to graft failure. Graft rejection was
shown in 1 out of 3 explanted grafts.
Concusion: we report a concept, which may circumvent the problem of biologic graft degeneration. Limb salvage was
possible in 75% at 12 months in otherwise difficult circumstances.
Key Words: Critical limb ischaemia; Arterial transplantation; Homograft; Atherosclerosis; Redo infrapopliteal repair; Limb
salvage.
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For patients with limb threatening femoro-distal
occlusive disease bypass-grafting with autologous
greater saphenous vein is regarded as the treatment
of choice.1±6 When no autologous vein is present, the
use of glutaraldehyde preserved human umbilical
vein has been reported to yield acceptable long-term
results.7±9 Prosthetic material, even with adjunctive
procedures such as patches or cuffs, often fails to
show adequate patency rates at one year in the tibial
position.10,11 In the early days of vascular surgery,
preserved arterial and venous12±15 homografts were
used for vascular repair. However, the concept was
soon discarded because of the high rate of aneu-
rysm formation and dissections attributed to bio-
degeneration.16,17 Preservation techniques often led
to early thrombotic graft occlusion. Recently, vascularPlease address all correspondence to: Univ. Prof. Dr. Th.
HoÈlzenbein, Klinische Abteilung fuÈ r GefaÈûchirurgie,
UniversitaÈtsklinik fuÈ r Chirurgie, Allgemeines Krankenhaus der
Stadt Wien, WaÈhringer GuÈ rtel 18 ± 20, A ± 1090 Wien, Austria.
1078±5884/02/040314 08 $35.00/0 # 2002 Elsevier Science Ltd. Allrepair with homografts employing improved preser-
vation protocols was revived for the management
of aortic graft infections and critical limb ischae-
mia.13,18 Nevertheless, graft degradation is still the
limiting factor for successful long-term performance
(Table 1).
Experience in liver and kidney transplant surgery
shows that arteries supplying transplants rarely
become thrombosed or aneurysmal19 even during
follow-up periods of 20 years or longer. In additition,
it has been shown that endothelial cell fixation at the
inner surface of autologous and alloplastic conduits
may improve patency in both above- and below-knee
reconstructions. An intact endothelium seems to be a
prerequisite for improved long-term patency of auto-
logous and alloplastic bypass grafts.20±22
We, therefore, adopted the hypothesis that a vital
endothelial coverage is of crucial importance to
achieve prolonged durability in arterial homografts.
This can only be achieved with fresh arterial grafts
implanted immediately after harvest. Our approach
included immediate arterial grafting minimising cold
ischaemia time with due attention to organ transplantrights reserved.
Table 1. Primary patency rates of tibial bypass surgery for limb salvage with conduits other than
greater saphenous vein.
Graft source Author Year Primary patency (%)
1-year 3-year
Arm vein Sesto1 1992 49 40
Harward2 1992 67 58
HoÈlzenbein44 1996 71 52
PTFE w/o adjuncts Fichelle53 1995 61 43
Parsons54 1996 71 39
Veith55 1986 46 30
PTFE with vein cuff Wijesinghe10 1998 68 Ð
PTFE with a-v fistula Ascer56 1996 78 61
PTFE with vein patch Taylor11 1992 74 58
PTFE with ECS Magometschnigg47 1992 45 36
Human umbilical vein Dardik9 1995 Ð 46
Cryopreserved vein Walker14 1993 28 Ð
Martin15 1994 37 Ð
Cryopreserved artery Albertini13 2000 49 35
Fresh Arterial Homograft Transplantation 315principles, such as ABO-compatibility, and lympho-
cyte cross-matching.
The feasibility of this preliminary approach has
been tested in a small series of patients with long-
standing history of peripheral vascular disease, in
whom major amputation was the only alternative.
The results are presented herein.
Methods
After approval was obtained from the local ethics
commissions (Ethics Commission of the Vienna Uni-
versity Medical School and of the Vienna General
Hospital; EK 456/1999) a clinical observational trial
was implemented. All patients gave informed consent
to the experimental design of the protocol. Data have
been collected prospectively.
Patient selection
Patients in this series were operated on from 5/99 to
7/01. They have undergone at least one revascularisa-
tion procedure at the diseased extremity (Table 2). In
none of them was sufficient autologous material avail-
able for distal graft repair. All of them were operated
for limb salvage, with major amputation as the only
alternative. The majority of the patients (9/13) were
diabetic. Six out of 13 of the patients received their
initial reconstruction in another institution. In 3/13
patients the initial vascular reconstruction was for
claudication, 2 of them for life-style limiting, one of
them for disabling disease. All patients initially oper-
ated on for claudication were referred to our institu-
tion from another hospital. As patients entered
the study an intraarterial angiogram was performedwith a ruler to determine the approximate length of
graft needed for reconstruction. HLA-type was deter-
mined and serum was stored for lymphocyte cross-
matching. Each graft was harvested from a blood
group-compatible organ donor and recipient cross-
match was performed before graft implantation.
Graft harvest
Arterial homografts were harvested from brain-dead
organ donors together with multiple organ harvest.
All donors were virologically screened for HIV, hepa-
titis B and C and CMV. Grafts were harvested by a
separate vascular surgical team. In general the graft
was harvested from the aortic bifurcation to the tibio-
peroneal trunk. The arterial anatomy of each graft is
given in Table 3. The hypogastric artery, the profunda
femoris artery and the anterior tibial artery were left
long to serve as access site for angiography, biopsy
and anastomotic patch plasty. Side branches were tied
at a distance of about 2±3 mm from the main graft to
preserve the vasa vasorum.23 A point was made to
keep the endothelium intact by atraumatic harvesting,
perfusing and storing the grafts in a preserving agent
(HTK, UW). Before use, all graft were checked with
angioscopy to detect inferior segments of the graft. All
grafts were stored then in preservation solution at 4 C
immediate to implantation.
Grafts were harvested for each patient, according to
a `` waiting list''. The department runs a busy trans-
plantation centre averaging 180±250 kidney transplan-
tations a year, and therefore a sufficient number of
donors is usually available for an average of 6 recipi-
ents per year. The individual waiting time for a com-
patible graft depends on the recipient's blood type.Eur J Vasc Endovasc Surg Vol 24, October 2002
Table 2. Clinical details, vascular history, indication for surgery and run-off score of the 13 patients undergoing 14 femorodistal
procedures.
No. Init. Sex/age (years of
vasc. disease)
Previous vascular
surgery
No. of previous surgeries
in the ipsilateral leg
Indication Run-off score
(Rutherford)
1 M. J. M/61 (8) L CFA-AK iGSV 5 gangrene 2.5
L CFA-AK ePTFE
L CFA-BK ePTFE
L EIA-CFA ePTFE
L profundaplasty (arm vein)
2 P. H. M/58 (6) R CFA-PT iGSV 2 gangrene 3
L CFA-ATPER iGSV
R profundaplasty
L veingraft patch plasty
Multiple HD access bilat.
Kidney transplantation
3 H. F. M/62 (4) CABG 2 gangrene 7
R CFA-BK iGSV
R CFA-PER arm vein
4 K. F. M/59 (4) CABG 2 gangrene 8
R CFA-BK
L CFA-AK ePTFE
L CFA-AT arm vein
5 K. J. M/45 (8) L multiple PTA 1 rest pain 7
R CFA-BK (iGSV)
R above-knee amputation
6 M. F. F/79 (12) CABG (iGSV) 5 gangrene 3
R CFA-AK (cGSV)
L CFA-BK ePTFE
R CFA-BK ePTFE
L above-knee amputation
R CFA-AK ePTFE
R CFA-BK ePTFE seeding
R CFA-BK ePTFE
7 M. H. M/56 (6) L CFA-AK iGSV 4 gangrene 5
R CFA-AK iGSV
R BK jumpgraft cGSV
R PT jumpgraft iGSV
Thrombectomy of PT jumpgraft
8 R. M. F/61 (8) CABG 1 gangrene 1
redo CABG
R profundaplasty iGSV
Cardiac transplantation
9 K. R. M/71 (5) CABG (iGSV) 1 gangrene 5
L CFA-AK iGSV
L BK-DP jumpgraft armvein
R profundaplasty
10 B. H. M/64 (3) Bilat GSV stripping 1 gangrene 7
L BK-DP arm vein
R BK-DP arm vein
11 W. R. M/70 (7) L CFA-AK iGSV 1 gangrene 7
CABG (cGSV)
12 Z. H. M/63 (9) aorto-bifemoral graft 5 rest pain 3
R CFA-AK iGSV
R CFA-AK ePTFE
TE of R CFA-AK ePTFE
R EIA-BK cGSV
R EIA-BK thrombectomypatchplasy
13 Z. H. M/63 (9) aorto-bifemoral graft 7 rest pain 5
R CFA-AK iGSV
R CFA-AK ePTFE
TE of R CFA-AK ePTFE
R EIA-AK arm vein
R EIA-L BK ATX
L LSV Interpositiongraft
14 W. H. M/65 (4) R CFA-AT iGSV 3 gangrene 7
R Prof-PER arm vein
R Prof-PER thrombectomy
M: male, F: female, L: left, R: right, i: ipsilateral, c: contralateral; EIA: external iliac artery, CFA: common femoral artery, Prof: profunda
femoris artery, AK: above-knee popliteal artery, BK: below-knee popliteal artery, AT: anterior tibial artery, PT: posterior tibial artery, PER:
peroneal artery, DP: dorsalis pedis artery, PLANT: plantar artery, GSV: greater saphenous vein, LSV: lesser saphenous vein; TE: thrombect-
omy, ePTFE: expanded polytetrafluorethylene, HD: haemodialysis.
Table 3. Donor details, graft anatomy and procedural details in 13 patients undergoing 14 femorodistal ATX procedures
No. DOS Donor
sex/age
Graft harvested
(Donor)
Preservation
agent
Storage
time (h)
Blood group
match
Crossmatch Bypass anatomy
(Patient)
Graft flow
before/after
papaverine
(ml/min)
1 7/99 M/26 AO!BK UW 3 A!A neg L CFA-AT 29/161
2 12/99 M/30 AO!BK UW 13 A!A neg R CFA-AT 32/180
3 12/99 M/27 AO!BK UW 5 A!A neg R EIA-PER 24/110
4 1/00 M/23 AO!BK HTK 13 A!A neg L CFA-AT 35/178
5 3/00 F/19 CIA!BK UW 12 O!A neg L CFA-AT 20/155
6 3/00 M/19 CIA!BK UW 15 O!A neg EIA-AT 43/188
7 5/00 F/26 EIA!BK HTK 11 A!A neg R AK-Plant 35/215
8 5/00 M/25 CIA!BK UW 6 O!A neg R CFA-AT 26/160
9 7/00 F/44 CIA!AK UW 6 O!B neg R CFA-AK 38/201
10 2/01 M/28 CIA!BK UW 6 A!A neg R AK-DP 25/128
11 1/01 F/35 AO!BK UW 13 A!A neg L CFA-BK-AT 35/160
12 3/01 F/16 AO!BK HTK 6 O!A neg L EIA-R BK 32/111
13 5/01 M/22 AO!BK HTK 8 A!A neg L CFA-R AT 22/142
14 5/01 M/25 CIA!BK UW 9 AB!AB neg R CFA-AT 31/142
No.: patient number, M: male, F: female, DOS: date of surgery, UW: University of Wisconsin solution, HTK: Bretschneider's solution L: left,
R: right, AO: aortic bifurcation, CIA: common iliac artery, EIA: external iliac artery, CFA: common femoral artery, AK: above-knee popliteal
artery, BK: below-knee popliteal artery, AT: anterior tibial artery, PER: peroneal artery, DP: dorsal pedal artery, Plant: common plantar artery.
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Implantation was performed as soon as possible after
graft harvest to minimise graft cold ischaemia. Grafts
were implanted with the usual surgical techniques
performing proximal anastomosis first to allow the
graft to lengthen with arterial blood pressure. The
graft was then gently stretched before suturing
the distal anastomosis.
Intra-operative asessment was performed using
completion angiography, intra-operative completion
duplex scan and flow measurements with and with-
out papaverine injection. All grafts were placed sub-
cutaneously to facilitate clinical follow-up, duplex
surveillance, and graft revision.
Immunosuppression
Patients received an immunosuppressive regimen
employed for renal transplantation in our department
(prednisolone, cyclosporin A, mofetil mycopheno-
late). This regimen was discontinued in the case of
permanent graft loss. Cyclosporin doses are adjusted
to blood levels of 80±110 ng/ml.
Graft surveillance
Patients were seen in monthly intervals in the outpa-
tient department to check for cyclosporin A and myco-
phenolate levels. Graft patency was checked at every
visit. In addition, colour duplex studies were per-
formed every three months, and MR-angiograms atone year postoperatively. No patient was lost for
follow-up. Criteria for patency were according to
Rutherford.24
Statistics
Data were given as median, minimum and maximum
(range); mean follow-up was estimated according to
the method of Kaplan and Meier.25 Given the rela-
tively small series and the thus high variability,
patency rates were not calculated but presented in
a merely descriptive manner.
Results
To date 13 patients (M/F 11/2) with a median age of
62 years received 14 fresh arterial homografts. Indica-
tion for surgery was rest pain in 2, ischaemic tissue
loss and gangrene in 11 patients and urgent re-do ATX
because of anastomotic bleeding necessitating emer-
gency graft explantation on postoperative day 14 after
his first ATX (CFA-BK). The patients' vascular his-
tories are shown in Table 2. The run-off was measured
according to Rutherford,24 the median index was 5
(range: 1±8). Details of the surgical revascularisation
and the donor are shown in Table 3. Donors' mean age
was 31 years. Donor grafts were compatible with the
recipient's blood type in all cases. All crossmatches
prior to implantation were negative. The mean cold
ischaemia time was 9 hours. Intraoperatively, comple-
tion angiographies, duplex scans and electromagneticEur J Vasc Endovasc Surg Vol 24, October 2002
Fig. 1. Cumulative primary and secondary patency after ATX. STD: standard deviation; cumulative primary patency, mean: 10 months;
cumulative secondary patency, mean: 13 months.
318 M. Prager et al.flow measurements were performed in all cases. Basic
flow measurements showed a median value of 33 ml/
min (range: 22±43), the post-papaverine-injection-
median-value was 164 ml/min (range: 110±215). Via-
bility of the graft was proven by cell culture of the
graft in all cases. Endothelial viability was assessed
from a side branch (usually from the profound fem-
oral or the internal iliac artery) of the graft at the time
of implantation in cooperation and according to the
method of J. Meinhard.22,26,27 We did not take speci-
mens from functioning grafts and, untill now, we did
not feel the necessity for biopsy. Nevertheless, a
biopsy is practically feasible, because we always
leave a long profound femoral artery branch in a
subcutaneous position, marked with haemoclips, for
possible biopsy in local anaesthesia during follow-up.
The mean follow-up time has so far been 12 months.
There was no patient lost for follow-up. Five out of 12
have primary patent conduits with a mean follow-up
of 8 months (4, 5, 7, 15 months). Three out of 12
patients have secondary patent grafts (13, 20, 25
months). In one patient early anastomotic bleeding
necessitated graft explantation and early replacement
with a cross-over CFA to AT re-do ATX after 5 days.
This graft is patent at 5 months. One had successfull
surgical thrombectomy at 8 weeks after ATX, one had
PTA at 10 months because of failing graft and one
had two thrombolysis procedures at 2 and 4 monthsEur J Vasc Endovasc Surg Vol 24, October 2002postoperatively, yielding a secondary patent graft for
13 months. Four patients developed permanent graft
thromboses. In one case the graft (occlusion at
2 months after transplantation) could not be salvaged
and the patient underwent below-knee amputation on
day 48 after graft occlusion. In a second patient surg-
ical thrombectomy failed to restore patency and the
patient had to undergo above-knee amputation (AKA)
on day 3 after ineffective thrombectomy. In a third
patient there was effective thrombolysis at 4 months.
The patient developed rethrombosis of the conduit at
13 months, but re-thrombolysis failed and BKA had to
be performed. In all, 8/12 patients have patent recon-
structions at a mean follow-up of 12 months (Fig. 1).
All patients are on an anticoagulant regimen with
phenprocoumon.
Wound healing ± postoperative complications
Surprisingly, we did not observe any wound prob-
lems. One patient had impaired healing of a lesser
saphenous vein harvest site, which later on could be
resolved by mesh-grafting. The healing of acral/fore-
foot amputation sites seemed comparable to patients
with conventional revascularisations. There was per
primam healing of all anastomotic arterial access
wounds.
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Arterial homografts have been proven to be suitable
conduits for distal revascularisation in critical ischae-
mia.13,28,29 There has been long-standing experience
with preserved vein grafts, yielding excellent early
results.30±34 Nevertheless, long-term results have
been disappointing, due to late graft degeneration.16
It has been shown that the endothelial lining and
the muscle cells of the graft are lost by the preserva-
tion process.12 Several factors are responsible for the
disappearance of these cells in both, arterial and
venous, homografts. Toxicity of preserving agents,
particularly with antibiotics added, events during
cryopreservation, spontaneous cell death, and finally
destruction of surviving cells by immunocompetent
host cells12,35 allegedly cause endothelial loss. The
lack of surviving cells may well play a role in graft
degeneration.
On the other hand it has been demonstrated that
endothelial integrity plays a major role in cardiovas-
cular medicine in general21 and particularly for early
and late graft patency in vein grafts20 and seeded
allografts as well.22 In order to improve homograft
patency and to prevent degeneration, endothelial pre-
servation seems to be of crucial importance.
Biodegeneration is hardly ever seen in solid organ
transplantation. Arteries supplying solid organ trans-
plants, although short, are seemingly exposed to the
same risk factors for degeneration as arterial homo-
grafts. The only difference consists of the lack of a
preservation process of the vascular pedicles of solid
organ transplants, followed by the implantion with
short ischaemia time and the consequent immunosup-
pressive therapy of the organ recipient.
Fresh arterial homograft with immunosuppres-
sion for the purpose of prevention of graft rejection
has not yet been employed Da Gama et al.23 presented
a series of cryopreserved arterial homografts in 13
patients receiving azathioprine, cyclosporin, and
prednisone therapy for previous kidney transplant-
ation. He could demonstrate that immunosuppression
modified host tolerance to arterial allografts, improv-
ing their biological behaviour, a fact that was already
documented previously in animal experiments with
FK 506,36 low and therapeutic dosages of cyclosporin
A,37 and with cyclosporin A and mycophenolate
mofetil.38
The regimen described for fresh arterial transplanta-
tion in animal models is difficult to transfer to
humans.38 Quadruple immunosupressive therapy
may well lead to reduced graft rejection, but may
lead to disturbed wound healing in these patients,
mostly presenting with gangrene. In addition, most ofthese patients will have a reduced renal function,
exposing them to a therapy with cyclosporin A may
lead to further reduction of renal function. We have
chosen a mild immunosuppressive regimen employ-
ing a triple therapy: (1) Immunosuppression is
induced with high doses of cortisone and maintained
with 5 mg of predisone daily. (2) Mycophenolate
mofetil is given is related to of leucocyte counts and
(3) cylosporine A to serum levels of 80±100 ng/ml.
Rejection monitoring of these grafts is a major
unsolved problem still. There are no biochemical mar-
kers and histologic evaluation is impossible, due to
difficulties in obtaining an in vivo biopsy. Histologic
examination in our cases has been possible only after
graft explantation or during open graft thrombectomy.
Although there are hints that intimal oedema may be a
sign of rejection, which can be picked up by modern
duplex equipment, histologic confirmation is still
lacking.
As most of our patients presented with infected
tissue necrosis as indication for surgery, additional
exposure to immunosupression was a major concern.
Improved circulation may, however, play an intrinsic
role in wound healing. Thus, immunosuppression did
not hamper surgical success in our patients presenting
predominantly with local infected trophic acral
lesions. This has been confirmed by Posner et al.,
who reported on 19 patients receiving cryopreserved
homograft saphenous vein used for infrageniculate
arterial reconstructions under an immunosuppressive
protocol consisting of low-dose cyclosporin A,
azathioprine and prednisone.39
Furthermore, the use of homografts shortens oper-
ating time and reduces operative trauma, because the
conduit harvest is transferred to the organ donor
operation. After the harvest of a conduit of optimal
quality and length, the arterial exposure and the
anastomoses can be performed at the optimal sites.
Veno-venostomies of multiple vein segments can be
avoided. The operative procedure can be carried out
under local anaesthesia.
Most series dealing with bypass procedures using
conduits other than greater vein are dealing with
primary and secondary revascularisation proce-
dures.2,3,40±43 Patients included in this project did not
have arm veins or other conventional non-greater
saphenous vein resources like lesser saphenous vein
left for reconstruction. Without any doubt, arm veins
play an intrinsic clinical role in re-do surgery for limb
salvage, if the greater saphenous vein is not avail-
able.41,44,45 The extensive use of arm veins is part of
our department's revascularisation policy.
Series of tertiary and quaternary bypass procedures
are scarce. New graft insertion has been reported asEur J Vasc Endovasc Surg Vol 24, October 2002
320 M. Prager et al.the method of choice for graft failure.46 Yet, there are
no reports available of patient series with a compar-
able vascular surgery history in need of a distal
revascularisation. In these patients, currently three
options may be available: amputation, re-do grafting
with human umbilical vein grafts or artificial
material with or without adjuncts or use of a pre-
served homograft.
Without any doubt, autologous conduits are the
conduit of choice for infrainguinal revascularisation.
In contrast to da Gama's report, our pilot study cohort
consisted exclusively of worst case±end stage patients
receiving predominantly tibial or pedal revascularisa-
tion. Yet, experience with endothelial cell seeding is
limited to the popliteal and proximal tibial level47±49
and virtually non-existent for the pedal arteries. Des-
pite its beneficial results (Table 1) cell seeding has not
gained universal acceptance because of the complex
and time-consuming lab work needed to prepare and
seed the endothelial cells. The preparation of conduits
consists mainly of tissue culture techniques during a
time period of several weeks.
Preservation provides for long-term stability thus
ensuring storage in artery banks. In addition, it virtu-
ally rules out hepatitis and HIV/AIDS transmission.
While reducing the antigenicity of grafts,50,51 cryo-
preservation with endothelial cell loss is probably
responsible for the homograft degeneration and con-
sequently of the poor long-term outcome of peripheral
vascular surgery. Cryopreservation should therefore
be reserved for exceptional clinical cases, such as
emergency procedures for graft infection.15
The limited availability of donor arteries continues
to be a problem inherent in the concept. As it is inex-
orably linked to organ transplant algorithms, the tech-
nique described will be reserved for vascular units in
close contact with organ transplant centres. As for
organ transplants, long waiting lists for donor arteries
may be a problem limiting the widespread use of the
technique.
Conclusion
Limb salvage is essential for the patients' activity and
social integration. It ensures independence in their
social environment. It has been demonstrated that
successful revascularisation will lead to improved
patient survival.52 Fresh arterial homotransplanta-
tions with immunosupression may well lead to limb
salvage long enough for the limited lifespan of these
morbid patients. Low-dose immunosupression seems
not to affect procedure-related morbidity.Eur J Vasc Endovasc Surg Vol 24, October 2002References
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